在心力衰竭患者的塞马格卢提德与保存的排泄分数和肥胖症
Mikhail N Kosiborod1, Steen Z Abildstrøm1, Barry A Borlaug1
1From the Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) - both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) - all in the United Kingdom; the Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); the Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto (S.V.), and University of Alberta, Edmonton (J.E.) - both in Canada; the College of Health and Medicine, the Australian National University, Canberra, ACT, Australia (W.A.); Max Super Specialty Hospital, New Delhi, India (V.C.); the Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden (M.F.); the Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan (H.I.); the Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland (M.L.); the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V.M.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, and CIBER (Centro de Investigación Biomédica en Red) Cardiovascular, Valencia, Spain (J.N.); Instituto de Cardiologia J.F. Cabral, Corrientes, Argentina (E.P.); ASST (Azienda Sociosanitaria Territoriale) Papa Giovanni XXIII, Bergamo, Italy (M. Senni); John Hopkins Hospital, Baltimore (K.S.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (P.V.M.); Medical University of Graz, Graz, Austria (D.L.); and Cardiology and Angiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany (D.W.).
在患有与肥胖有关的心力衰竭患者中,塞马格卢提德显著改善了症状和运动功能,并保留了喷射分数. 这种肥胖治疗也导致了大量的体重减轻和减少炎症.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭与保留喷射分数 (HFpEF) 的患病率正在上升,特别是在肥胖个体中.
- 与肥胖相关的HFpEF具有显著的症状负担和功能限制.
- 目前与肥胖相关的HFpEF的治疗选择有限.
研究的目的:
- 评估塞马格卢提德在治疗肥胖患者心力衰竭的疗效.
- 评估塞马格卢提德对症状,身体限制,运动功能和体重的影响.
主要方法:
- 一项随机试验,涉及529名HFpEF和体重指数≥30.0的患者.
- 参与者每周接受一次塞马格卢提德 (2.4毫克) 或安慰剂,持续52周.
- 主要终点包括堪萨斯城心肌病问卷临床总结得分 (KCCQ-CSS) 和体重的变化.
主要成果:
- 塞马格卢提德显著改善了KCCQ-CSS得分 (16.6比8.7分),并减少了体重 (-13.3%比-2.6%).
- 运动功能,以6分钟的步行距离来衡量,在使用西马格卢提德时显著改善 (+21.5m vs +1.2m).
- 赛马格卢提德还降低了C-反应蛋白水平,表明炎症减少,并且在严重不良事件方面具有更好的安全性.
结论:
- 2.4毫克的塞马格卢提德在减少HFpEF和肥胖患者的症状和身体限制方面表现出显著的益处.
- 与安慰剂相比,治疗导致更大的体重减轻和提高运动能力.
- 塞马格卢提德代表了一种有前途的治疗方法,用于管理与肥胖相关的HFpEF.
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Heart Failure V: Medical Management
Dipeptidyl Peptidase 4 Inhibitors
Obesity
Oral Hypoglycemic Agents: Biguanides and Glitazones
Heart Failure Drugs: Inotropic Agents


